CatSci Ltd and AGC Pharma Chemicals announce their strategic partnership

AGC says its customers can use Wales-based CatSci’s expertise in chemical and analytical development, crystallisation and solid form, pre-formulation, plus high potency active pharmaceutics ingredients (API) capabilities, alongside chemistry manufacturing and controls (CMC) for the development of their new therapeutics.

The companies believe streamlined tech transfer workflows will ensure a seamless process knowledge and information transfer from development to manufacturing.

With more than 40 years of small molecule CDMO and 60 years of API manufacturing experience, AGC offer their customers tailored solutions from early clinical stage to commercial stage. They provide chemical compounds in full compliance with environmental, health and safety, and cGMP international standards.

CatSci support pharmaceutical innovators at all stages of drug development and serve customers around the world developing economically and environmentally at all stages of drug development.

CatSci say they ‘help customers to navigate complex scientific challenges and address critical healthcare needs, including antimicrobial resistance, cancer, and mental health’.

Dr Jerome Théobald, the company's chief operating officer, said: “I am thrilled that CatSci is partnering with AGC Pharma Chemicals, and we are excited about what our partnership means for our customers. I am confident that AGC’s excellent cGMP manufacturing capabilities will add strategic value to our customers’ pipeline, accelerating their path to clinic.

“We are driven by our purpose to get new medicines into the hands of patients in need, and it was clear from the start that AGC Pharma Chemicals are aligned with us on this goal. Our partnership is built on our commitment to solve our customers’ challenges, allowing them to advance seamlessly through their pharmaceutical development from drug substance to drug product.”

The companies will work together to provide scalable small molecule API manufacturing, from grams to tonnes. Through this partnership, customers will get access to a wide range of manufacturing technologies including fluorination, bromination, hydrogenation, cryogenic, HPAPI, micronisation and continuous flow to support their complex manufacturing programmes.

Hiro Kadokura, AGC Pharma chemicals Europe’s chief executive officer, said: “It is great to have CatSci as a partner of AGC Pharma Chemicals, as we can provide seamless service to our customers from pre-clinical to the launch. Together with the strong cGMP CDMO capability of AGC Pharma Chemicals, and the excellent CRO capability of CatSci, we can cover especially early phase projects leveraging the effective expertise of each company. I am excited about this partnership that will bring great value to our customers.”